Skip to main content
OpenTrials
Completed

NCT Number: NCT02641015

Study to Assess Management and Outcomes of Hospitalised Patients With Complicated UTI (RESCUING)

A retrospective observational study to assess the clinical management and outcomes of hospitalised patients with complicated urinary tract infection in countries with high prevalence of multidrug resistant gram-negative bacteria (COMBACTE-MAGNET,WP5)

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Emergency Hospital Pirogov, Sofia, Bulgaria

Loading trial locations.

About this study

Bacterial resistance to antimicrobial drugs is a major public health problem. Of greatest concern is the rapid emergence and dissemination of resistance to third generation cephalosporins in Enterobacteriaceae, especially Escherichia coli and Klebsiella pneumoniae. This is frequently seen in association with resistance to other classes of antibiotics leading to a multidrug resistance (MDR) profile. These MDR isolates are often involved in complicated urinary tract infection (cUTI), and are associated with poor clinical outcomes. In addition, in the last decade there has been an emergence of carbapenemase-producing Enterobacteriaceae, which are also resistant to other antibiotics than carbapenems, leaving few therapeutic options.

The overall aim of this study is to provide information about the epidemiology, clinical management and outcome of patients hospitalised with cUTI, including pyelonephritis. To achieve this aim, the investigators will perform a multicentre retrospective observational study in patients with hospitalised cUTI. The study will be conducted in several European countries plus Israel, which have a high prevalence of MDR Gram-negative bacteria (GNB), including Pseudomonas aeruginosa. The study will seek to identify possible modifiable risk factors for treatment failure, especially those related to antibiotic therapy.

On completion of this study, the investigators will develop a better understanding of the clinical management of hospitalised patients with cUTI due to MDR GNB in European countries. The investigators will identify the modifiable risk factors for treatment failure. This information will be used to inform better clinical and antibiotic management of cUTI to improve patient outcomes. The study will also be used in the development of hypothesis for future randomised controlled trials in cUTI with new antibiotics. Dissemination of results will take place through peer-reviewed publications and conference presentations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with UTI and at least one of the following underlying conditions:

  • Indwelling urinary catheter
  • Urinary retention (at least 100ml of residual urine after voiding)
  • Neurogenic bladder
  • Obstructive uropathy (e.g. nephrolithiasis, fibrosis)
  • Renal impairment caused by intrinsic renal disease: Estimated glomerular filtration rate (eGFR) <60 mL/min
  • Renal transplantation
  • Urinary tract modifications, such as an ileal loop or pouch
  • Pyelonephritis and normal urinary tract anatomy

and at least one of the following signs or symptoms:

  • Chills or rigors associated with fever or hypothermia (temperature greater than 38ºC or below 36ºC)
  • Flank pain (pyelonephritis) or pelvic pain (cUTI)
  • Dysuria, urinary frequency, or urinary urgency
  • Costo-vertebral angle tenderness on physical examination
  • UTI-related altered mental state

and at least one of the following microbiological results:

  • Urine culture with at least 105 CFU/mL or greater of a uropathogen (no more than 2 species)
  • At least one blood culture growing possible uropathogens (no more than 2 species) with no other evident site of infection

Exclusion criteria

  • Patients less than 18 years of age
  • Prostatitis
  • Polymicrobial infections that include Candida spp.
  • Polymicrobial infections that include more than 2 bacterial species
  • cUTI with Candida spp. as sole uropathogen

Treatment and study plan

Primary outcomes

  1. Treatment Failure

    Time frame: 30 days

    Treatment failure will be assessed as number of participants with evidence of treatment failure or mortality within 30 days from initial cUTI diagnosis

Secondary outcomes

  1. Time to clinical response

    Time frame: 30 days

    Time to clinical response (in days), since initiation of antibiotic treatment

  2. Time to urological intervention for source control

    Time frame: 30 days

    Time to urological intervention for source control (in days) since initial cUTI diagnosis

  3. Time to death

    Time frame: 30 days

    Time to death (in days) since original cUTI diagnosis

  4. Duration of antibiotic therapy

    Time frame: 30 days

    Duration of antibiotic therapy (in days)

  5. Length of hospital stay

    Time frame: 30 days

    Length of hospital stay (in days)

  6. Hospital mortality

    Time frame: 30 days

    Hospital mortality during admission

  7. All cause mortality within 30 days of the original cUTI diagnosis

    Time frame: 30 days

    All cause mortality within 30 days of the original cUTI diagnosis

  8. All cause of mortality for two months after hospital discharge

    Time frame: 60 days

    All cause of mortality for two months after hospital discharge

  9. Cost per case of cUTI

    Time frame: 30 days

    Cost per case of cUTI

  10. Readmissions to the hospital within 60 days of hospital discharge

    Time frame: 60 days

    Readmissions to the hospital within 60 days of hospital discharge

  11. Adverse events related to antibiotic treatment including: moderate or severe allergic reactions, severe renal impairment, Clostridium difficile infection

    Time frame: 30 days

    Adverse events related to antibiotic treatment including: moderate or severe allergic reactions, severe renal impairment, Clostridium difficile infection

Sponsors and collaborators

Lead sponsor

Institut d'Investigació Biomèdica de Bellvitge

Other

Collaborators

  • AiCuris Anti-infective Cures AG
  • Tel Aviv University
  • UMC Utrecht
  • University of Bristol

Registry information

Official study title

A Retrospective Observational Study to Assess the Clinical Management and Outcomes of Hospitalised Patients With Complicated Urinary Tract Infection in Countries With High Prevalence of Multidrug Resistant Gram-negative Bacteria.

Acronym: RESCUING

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Dec 29, 2015
Registry last updated
Jan 18, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.